Abstract 434P
Background
A number of provincial online treatment guidelines/protocols exist in Canada, which differ in the information contained and the ease of use. Currently there is no national evidence-based, consensus-driven cancer treatment protocol for use at the point of care. The aim of such a resource would be to support Medical Oncologists (MOs) in the delivery of cancer treatment at the clinic interface and potentially improve patient outcomes by reducing treatment variation across Canada.
Methods
The study was conducted in two stages. Available provincial cancer treatment protocols were evaluated with regards to: content for chemotherapy, immunotherapy, ease of use, toxicity, dosing recommendations, reference studies. Canadian MOs were invited to participate in an anonymous survey distributed through the Canadian Association of Medical Oncologists. The assessment included: current online resources (OR) used, information provided, ease of use, relevance to point of care use, need for a national Canadian resource. MOs were asked to review a comparator Pan-Australian OR.
Results
40/327 responded: 28% BC, 26% ON and the rest from other provinces. 82%, 54% and 23% respectively used the BC and ON and other provincial ORs. 50% used ≥2 websites. 62% found the website of choice easy to use, 33% felt it had updated immune therapy information and 26% felt it was updated regularly. The OR used met the MO need for dose/scheduling in 87.5% cases but only 50% and 37.5% cases for AEs and reference information respectively. Criteria evaluated in the ORs included: dosing, toxicity modification, AEs, monitoring, references and other criteria. 95% of MOs felt that a single portal aimed at point of care for Canadian MOs would be of value. 64% felt that the international comparator was better than the current OR being used.
Conclusions
There is variation in the current Canadian OR used by MOs in Canada with a need for national evidence-based, cancer treatment protocols/information for use at the point of care. To develop such a Pan-Canadian website resource, further analysis and infrastructure is required. Such a resource would potentially reduce treatment variability and augment quality of care delivered.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
371P - Real-world insights into treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): KINDLE study India analysis
Presenter: Kumar Prabhash
Session: e-Poster Display Session
372P - Treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): Real-world experience in Singapore from the KINDLE study
Presenter: Ross A. Soo
Session: e-Poster Display Session
373P - Chromatin accessibility reveals potential prognostic value of the peak set associated with smoking history in patients with lung adenocarcinoma
Presenter: Jianlian Deng
Session: e-Poster Display Session
384P - BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
Presenter: Stefanie Schalm
Session: e-Poster Display Session
385P - Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
Presenter: Fabrice Barlesi
Session: e-Poster Display Session
386P - A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: LI Zhou
Session: e-Poster Display Session
387P - Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C
Presenter: Tomonori Hirashima
Session: e-Poster Display Session
388P - Biosimilar TAB008 compared with bevacizumab in advanced non-squamous, non-small cell, EGFR wildtype lung cancer patients
Presenter: Zhen Zhou
Session: e-Poster Display Session
389P - Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%
Presenter: Yi-Long Wu
Session: e-Poster Display Session
391P - Economic impact of next-generation sequencing (NGS) versus single-gene testing modalities to detect genomic alterations (GAs) in metastatic non-small cell lung cancer (mNSCLC) in Asia
Presenter: Herbert Loong
Session: e-Poster Display Session